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Abstract
Background: The robust generation of human hematopoietic progenitor cells from induced or embryonic
pluripotent stem cells would be beneficial for multiple areas of research, including mechanistic studies of
hematopoiesis, the development of cellular therapies for autoimmune diseases, induced transplant tolerance,
anticancer immunotherapies, disease modeling, and drug/toxicity screening. Over the past years, significant
progress has been made in identifying effective protocols for hematopoietic differentiation from pluripotent
stem cells and understanding stages of mesodermal, endothelial, and hematopoietic specification. Thus, it
has been shown that variations in cytokine and inhibitory molecule treatments in the first few days of hematopoietic
differentiation define primitive versus definitive potential of produced hematopoietic progenitor cells. The majority
of current feeder-free, defined systems for hematopoietic induction from pluripotent stem cells include prolonged
incubations with various cytokines that make the differentiation process complex and time consuming. We established
that the application of Wnt agonist CHIR99021 efficiently promotes differentiation of human pluripotent
stem cells in the absence of any hematopoietic cytokines to the stage of hemogenic endothelium capable
of definitive hematopoiesis.
Methods: The hemogenic endothelium differentiation was accomplished in an adherent, serum-free culture system by
applying CHIR99021. Hemogenic endothelium progenitor cells were isolated on day 5 of differentiation and evaluated
for their endothelial, myeloid, and lymphoid potential.
Results: Monolayer induction based on GSK3 inhibition, described here, yielded a large number of CD31+CD34+
hemogenic endothelium cells. When isolated and propagated in adherent conditions, these progenitors gave rise to
mature endothelium. When further cocultured with OP9 mouse stromal cells, these progenitors gave rise to various
cells of myeloid lineages as well as natural killer lymphoid, T-lymphoid, and B-lymphoid cells.
Conclusion: The results of this study substantiate a method that significantly reduces the complexity of current
protocols for hematopoietic induction, offers a defined system to study the factors that affect the early stages of
hematopoiesis, and provides a new route of lymphoid and myeloid cell derivation from human pluripotent stem cells,
thus enhancing their use in translational medicine.
Keywords: Hemogenic endothelium, Pluripotent stem cells, Hematopoietic cells, Lymphocytes, Glycogen synthase
kinase 3 inhibitor
* Correspondence: v-galat@northwestern.edu
5Department of Pathology, Developmental Biology Program, Stanley Manne
Children’s Research Institute, Ann & Robert H. Lurie Children’s Hospital of
Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL,
USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Galat et al. Stem Cell Research & Therapy  (2017) 8:67 
DOI 10.1186/s13287-017-0519-0
Background
Recently, substantial progress has been made in
hematopoietic differentiation of human pluripotent stem
cells (hPSCs) [1–4]. In combination with gene correction
systems, hematopoietic differentiation provides an av-
enue for disease modeling [5, 6] and cellular therapies
[7, 8]. Transplantation of hematopoietic stem cells
(HSCs), which originate via the definitive hematopoietic
program, offers potential treatment for a variety of
hematological disorders [9, 10]. The hallmark of defini-
tive hematopoiesis is the capacity of hematopoietic pro-
genitors to produce cells of lymphoid lineage [11]. To
date, the generation of various types of lymphoid cells,
such as T lymphocytes ([12–14], reviewed [15]), natural
killer (NK) cells [16], and induced NK (iNK) cells [17],
and limited lymphoid B-cell potential [18] from hPSCs
has been reported.
Nevertheless, the development of a fully defined
system for generation of functional hematopoietic cell
types, especially lymphocytes, remains a significant chal-
lenge. The identification of molecular mechanisms and
factors driving the hematopoietic specification of various
blood lineages from hPSCs is critical in overcoming this
limitation [19]. Originally, hematopoietic induction was
established by coculture with mouse stromal cells [20].
Currently, there are two main approaches to refining the
conditions for induction of blood lineages. The first is
based on selection of appropriate transcriptional regula-
tors in gain-of-function experiments [21–23]. The sec-
ond approach relies on the development of a cytokine
regimen based on manipulations of the pathways of em-
bryonic hematopoiesis [13, 24–26]. Several major stages
were described during initial hematopoietic specification
in the embryo [27] and in human pluripotent cells:
APLNR+ primitive streak/mesendoderm precursors
(mesenchymoangioblasts), VE-cadherin+/CD31+ angio-
hematopoietic progenitors, hemogenic endothelium
(HE), and multipotential hematopoietic progenitors [1].
BMP4, Activin A, and bFGF are commonly used to
induce mesodermal commitment of pluripotent cells.
Subsequent stages of hemato-vascular differentiation are
typically supplemented with combinations of VEGF,
bFGF, IL-6, IL-3, IL-11, IPO, IGF1, and SCF [28].
The signaling landscape is crucial for fate determin-
ation at the initial stages of differentiation. Apparently,
primitive and definitive hematopoietic specification seg-
regates in the very early steps of hPSC differentiation
and can be distinguished by Glycophorin A (CD235a)
expression by the second day after induction. In particu-
lar, it was shown that specification of definitive progeni-
tors (CD235a−) requires Wnt–b-catenin signaling [11].
The glycogen synthase kinase 3 (GSK3) inhibitor
CHIR99021 is a known Wnt agonist [29]. GSK inhibition
was shown to induce hPSC differentiation to vascular
progenitors [30, 31] and definitive hematopoietic cells in
cell aggregates [11]. In combination with an OP9 cocul-
ture system, this was also shown to facilitate the devel-
opment of hematopoietic progenitors in primates [32].
Here, we demonstrate that exposure of hPSCs growing
in adherent culture to the inhibitor of glycogen synthase
kinase 3 (GSK3 inhibitor) induces their specification to a
definitive HE without the addition of any cytokines.
Once transferred to the appropriate culture conditions,
these endothelial progenitors are capable of producing
lymphoid cells (NK, T and B cells) as well as various
cells of myeloid lineage. This finding provides a signifi-
cant advance in defining critical components for the
induction of definitive hematopoiesis in vitro. By redu-
cing the complexity of hematopoietic induction, this




The iPSC-SR2 line was derived from MRC-5 fibroblasts
(ATCC) by overexpressing Oct4, Sox2, Nanog, and cMyc
using retroviral vectors (pMXs-cMyc, pMXs-Klf4,
pMXs-hOct3-4, and pMXs-Sox2; Addgene) [33]. The
retroviral vectors were produced by transient transfec-
tion of 293 T cells. The fibroblasts were incubated in the
viral supernatants containing 5 μg/ml polybrene (Sigma)
for 4 h. The transduced cells were then incubated for
3 weeks until development of the pluripotent clones.
After isolation the clones were grown in mTeSR1
medium (Stem Cell Technologies) on a Matrigel® sub-
strate (BD Biosciences). The cultures were split mechan-
ically using the StemPro EZ Passage tool (Invitrogen).
OP9 coculture induction
hPSCs were maintained on irradiated embryonic mouse
fibroblasts (MEFs) in DMEM–F12 medium supple-
mented with serum knockout replacement, L-glutamine,
nonessential amino acid, and basic FGF (4 ng/ml). On
day 7 after the last passage, hPSCs were treated with col-
lagenase IV (1 mg/ml) for 5 min. Clumps of hPSCs were
collected and transferred into OP9 stromal cells supple-
mented with 10 ml of MEM-Alpha medium containing
G-Max (Invitrogen) and 20% FBS (HyClone). Next day,
medium was replaced with 20 ml of differentiation
media containing 10% FBS (HyClone), MTG (100 μM),
and ascorbic acid (50 μM) and thereafter was changed
every 4 days. The cells were collected on day 8 of
differentiation.
CHIR99021 induction
HE differentiation was established by a monolayer in-
duction protocol. Basically, as described previously [30],
single cells were plated on 60-mm culture dishes coated
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with Matrigel® and cultured overnight in iPS-Brew or
mTeSR1. Differentiation was induced with an induction
media containing advanced DMEM/12 (Life Technolo-
gies), glutamax (2.5 mM), ascorbic acid (60 μg/ml), and
CHIR990921 (6 mM) added on day 0. On day 2 of in-
duction CHIR990921 was removed from the media. The
cells were collected on day 5 of differentiation. HE cells
were isolated with positive selection of CD34+ cells on
magnetic columns (Miltenyi Biotec).
Endothelial cells
Endothelial cells (EC) were cultured in Vasculife media
(Life Line Cell Technologies). The endothelial potential
of EC was evaluated using a tube formation assay, im-
munostaining for von Willebrand Factor (vWF), and
acetylated-low density lipoprotein (Ac-LDL) uptake.
Regarding the tube formation assay, EC were seeded
onto a 12-well plate coated with Matrigel® (BD Biosci-
ences) at a density of 4.5 × 104 per well and incubated in
Vasculife medium overnight at 37 °C, 5% CO2. Ac-LDL
uptake was performed using a commercial kit (Biomed-
ical Technologies) in accordance with the manufacturer’s
instructions. EC were seeded onto 0.1% gelatin-coated
(Sigma) plates at a density of 2.5 × 105 cells per well in a
six-well plate. Ac-LDL was diluted to 10 μg/ml in
complete Vasculife medium and added to the cells for
3 h. The cells were then washed with Vasculife medium
and analyzed via florescent microscopy. Expression of
vWF was confirmed by staining EC using primary anti-
hvWF A2 antibody (R&D systems) and the appropriate
secondary antibody (Alexa-Fluor).
Hematopoietic colony forming assay
The hematopoietic colony forming assay was per-
formed in MethoCult H4435 medium (Stem Cell
Tech) supplemented with Flt-3 L, IL-7, IL-3, SCF, and
TPO (PeproTech, NJ, USA).
Cytospin analysis
The cells were collected into 150 μl of PBS containing
10% FBS, placed into a Shandon EZ Single Cytofunnel
(Thermo Scientific, MA, USA), and spun at 1000 rpm
for 5 min. The slides were then air dried, fixed with
methyl alcohol, and stained with Wright Stain (Fisher
Scientific, MA, USA).
Lymphocytes
Lymphocytes were derived by coculture of progenitor
cells with OP9-DLL4 stromal cells [11]. On day 5 of
monolayer culture, cells were treated with 0.05% Tryp-
sin–EDTA (Gibco) and plated on semi-confluent dishes
of OP9-DLL4, supplemented with differentiation
medium containing IL-7 (10 ng/ml), IL-3 (5 ng/ml),
hFlt-3 L (50 ng/ml), and hSCF (10 ng/ml) (all cytokines
purchased from PeproTech). On day 3 of OP9-DLL4 co-
culture, semi-adherent cells were collected and passaged
into a new dish with OP9-DLL4 cells. After this, floating
cells were passaged to new plates every 4–5 days for a
period of 14–30 days.
Microscopy
Confocal images were acquired using an LSM 510 META
Laser Scanning Microscope system (Zeiss, Thornmood,
NY, USA). By varying the width of the pinhole of the
detectors, the observed fluorescence was localized to a
known thickness of observed tissue and the depth of field
of the transmitted and DIC images was adjusted. Scale
bars were integrated into the image during acquisition.
Epifluorescence images were acquired on a Leica DM IRB
inverted microscope system (Wetzlar, Germany) using a
Hamamatsu ORCA-ER digital camera (Hamamatsu City,
Japan) controlled with Improvision Openlab software
version 5.0.2 (Lexington, MA, USA). Scale bars were
calibrated to each objective magnification and added after
acquisition. Light microscopic images were acquired with
a Nikon D100 (Tokyo, Japan) digital SLR camera on an
inverted Leica DM IRB microscope.
Immunocytochemistry
The cells were washed with PBS, fixed with 4% parafor-
maldehyde (PFA) for 5 min, and permeabilized with
0.1% Triton X-100 for 5 min. After 30-min incubation at
37 °C with blocking solution (Protein Block; Dako), cells
were incubated with primary antibodies (1:100) for 1 h
at room temperature. Secondary antibody (1:250) was
incubated for 30 min at 37 °C. Mounting medium con-
taining DAPI (Life Technologies) was used for counter-
staining nuclei. An alkaline phosphatase substrate kit
(Vector Laboratories Inc.) was used for detection of
alkaline phosphatase activity according to the manufac-
turer’s instructions.
Flow cytometry
Antibodies CD31, CD34, and CD144 were purchased
from Miltenyi Biotec. The cells were stained with the ap-
propriate conjugated antibodies for 30 min at 4 °C. Cells
were washed in a 0.5% BSA/PBS solution and analyzed
via FACSCalibur (BD Biosciences, San Jose, CA, USA).
Antibodies directed against CD3, TCRαβ, and TCRγδ as
well as the murine isotype-control antibody IgG1,k used
to assess background fluorescence for TCR expression
were obtained from BD Biosciences (San Jose). The sam-
ples that assessed TCR expression were acquired on a
FACS-Canto II flow cytometer (BD Biosciences, San
Jose) and analyzed using FlowJo software version 10.1
(Tree Star Inc., Ashland, OR, USA)
For flow cytometry analysis of NK cell differentiation,
the cells were labeled with a combination of monoclonal
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antibodies (mAbs) including CD45 Krome Orange
(Beckman Coulter) and CD56 PE, CD16 PE-Dazzle,
CD15 PerCP-Cy5.5, and CD94 APC (all from Biolegend,
San Diego, CA, USA). For the isotype controls, specific
mAbs were substituted for corresponding nonspecific
IgG isotypes. LIVE/DEAD Fixable Violet stain (ViVID;
Invitrogen, Eugene, OR, USA) was included to discrimin-
ate dead cells. Labeling was performed in 96-well U-
bottom plates using 2.5 × 105–3 × 105 cells in 50 μl of PBS
per well. After 25-min incubation with mAbs at 4 °C, cells
were washed twice, subsequently transferred into 5 ml Fal-
con tubes (BD Biosciences, Bedford, MA, USA), and proc-
essed on LSR-II (BD Biosciences, San Jose).
Compensation controls were prepared using an AbC
anti-mouse bead kit for mouse mAb capture and ArC
amine reactive compensation bead kit for ViVID
(both kits from Invitrogen), according to the manu-
facturer’s instructions. Data analysis was performed
using FlowJo software (Tree Star Inc.).
Results
GSK3 inhibition gives rise to hemogenic endothelium in
the absence of cytokines or mouse stromal feeder cells
Hemogenic endothelium (HE) can be produced by co-
culture with OP9 stromal cells or by the EB induction
method (reviewed by Slukvin [19]). In this study we use
embryonic stem cell lines H1 and H9 as well as induced
pluripotent stem cell (iPSC) line SR2 to show that a
large quantity of HE, capable of myeloid and lymphoid
differentiation, can be produced by GSK3 inhibition in
the absence of hematopoietic cytokines or mouse
stroma. The utilized hPSC line iPSC-SR2 was derived
from MRC-5 fibroblasts and shown to express a set of
characteristic pluripotency markers (Fig. 1a), had a
normal karyotype (Additional file 1: Figure S1A), and
met the criteria established for pluripotent cells based
on the evaluation of its whole genome expression
pattern using a PluriTest platform (Additional file 1:
Figure S1B). Additionally, hPSC line iPSC-SR2 was
shown to differentiate into derivatives of three main
embryonic lineages in vitro: endoderm [34], ectoderm
[35], and mesoderm [31, 36].
The timeline for the experiment is shown in Fig. 1b.
HE was derived on day 5 of differentiation and then
cocultured with OP9-DLL4 and various cytokines in
order to assess its hematopoietic potential. Particu-
larly, the differentiation of hPSCs cultured in
mTESR1 or iPSC-Brew was induced by culture with
glycogen synthase kinase 3B (GSK3) inhibitor
CHIR99021 (6 mM) for 2 days. The inhibitor was
then removed and the cells were subsequently cultured
in Advanced DMEM/F12, supplemented with ascorbic acid
for 3 more days. HE development was assessed by FACS
analysis as the percentage of CD31+ cells, on day 5 of
differentiation. The results were compared to the OP9 co-
culture method. As shown in Fig. 1b, although with some
variation, the cells cultured via the monolayer protocol gen-
erated more CD31+ cells than those cultured on OP9 in the
presence or absence of VEGF, which is known to enhance
hematopoietic cell differentiation (Fig. 1c). Notably, whereas
the cells generated on OP9 included CD31+CD43+ and
CD31+CD34+ suggesting that hematopoietic and endothe-
lial progenitors are produced, the monolayer induction
protocol CD31+ cells were all double positive for the
marker CD34+ (Fig. 1d) and generated no CD43+ cells
(data not shown). The absence of CD43+ cells was
also noted by Sturgeon et al. [11], who studied
hematopoiesis induced with cytokines in cell aggre-
gates and did not find CD43+ cells in the presence of
CHIR99021. They proposed that CHIR99021 inhibits
primitive hematopoiesis and promotes definitive
hematopoiesis, which expresses CD43+ at later stages
of development. Overall, using our CHIR99021 induc-
tion method, we were able to generate >4 × 105 CD31
+CD34+ HE cells per 1 × 105 hPSCs plated. When iso-
lated and propagated in adherent conditions, these
CD31+CD34+ progenitors gave rise to mature endo-
thelium similar to results described by Lian et al.
[30]. The endothelial characteristics of ECs were
confirmed with CD31+/VE-cadherin coexpression
(Fig. 1f ) and demonstrated in functional assays such
as Ac-LDL uptake (not shown), the tube formation
assay and immunostaining for vWF (1e).
These data thus demonstrate that the method intro-
duced here, which eliminated the need for cytokines,
culture on MEFs, and expensive media, does robustly
produce CD31+CD34+ double-positive HE.
Myeloid potential assessment
To demonstrate the myeloid potential of CD31+CD34+
HE derived by this monolayer culture method, we
assayed the hematopoietic colony forming potential. The
cells were briefly cocultured with OP9 and then plated
in methylcellulose media containing Flt3, IL-7, IL-3,
SCF, and TPO. The OP9 coculture was a necessary step
due to the fact that the hematopoietic commitment of
CD31+CD34+ progenitors is not revealed unless the cells
are cultured in hemogenic endothelial conditions or with
Notch ligand-expressing stromal cells [11]. We found that
the cells formed erythroid (CFU-E), granulocyte/macro-
phage (CFU-GM), macrophage (CFU-M), and multilineage
progenitor (CFU-GEMM) colonies (Fig. 2a). Notably, the
quantitative analysis of the colony forming units revealed
a trend for a relative proportion of colonies formed
after induction skewed toward the CFU-GM com-
pared with the relative proportion of colonies formed
after OP9 coculture, which contained the largest
number of CFU-E colonies (Fig. 2b). Colonies that
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formed after CHIR99021 induction and OP9 coculture
induction were identified using microscopic images of
colony morphologies and cytospin analysis of col-
lected colonies (Fig. 2c, d).
CHIR99021-induced hemogenic endothelium is capable of
efficient natural killer differentiation
The capacity to produce lymphocytes is a hallmark of
definitive hematopoiesis [11]. Lymphoid cell generation
Fig. 1 Derivation of CHIR99021-induced HE and iPSC-SR2 characterization. a Phenotypic characterization of iPSC-SR2: phase-contrast image of the
cells when grown on MEFs. Expression of alkaline phosphatase (AP, red) and of characteristic pluripotency genes (TRA 1-80 (green), Nanog (red),
and TRA 1-60 (green) and OCT4 (red) overlay) assessed by immunostaining. b Timeline of lympho-myloid differentiation and representative phase-
contrast image of hPSCs differentiating to vascular progenitors on day 5 after induction with the small molecule CHIR99021. c Induction efficiency
of CHIR99021-induced vs OP9 cocultured pluripotent cells as a percentage of CD31+ cells. Error bars are SEM of three independent experiments.
d Homogeneity of CD31+ double-positive cells obtained from CHIR99021 induction vs heterogeneous population obtained from OP9 coculture.
e At day 5, CD31+ cells were enriched with MACS selection column and quantified by flow cytometry for CD31 and CD144 expression.
Phenotypic and functional characterization of isolated cells: phase-contrast image of cells when grown in endothelial medium, tube
formation assay with calcein AM staining, expression of vWF assessed by immunostaining (red) overlay with Dapi, and
expression of VE-cadherin assessed by immunostaining. f Cytometric flow analysis demonstrating homogeneity of CD31+ and CD144
coexpression by vascular cells at passage 3. D day, hPSC human pluripotent stem cell, vWF von Willebrand factor
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from hPSCs in vitro is a long two-step process (40–60
days). Hematopoietic induction is usually performed
using stromal cells (e.g., OP9 or M210-B4) or using
embryoid bodies and cytokines. The second step for T
cells includes using OP9 cells expressing the NOTCH
ligands d-like 1 (DLL1) or d-like 4 (DLL4) [12–14],
reviewed by Smith et al. [15]. For NK cells, EL08-1D2 stro-
mal cell coculture and/or cytokines are used [16, 37, 38].
No efficient conditions have so far been reported for B-cell
differentiation from hPSCs.
To evaluate the lymphocyte-generating capabilities of
HE cells produced on day 5 after CHIR99021 induction,
we plated the cells onto OP9-DLL4 in MEM-Alpha
medium containing growth factor cocktail for lymphoid
cell differentiation. The medium contained MTG, ascor-
bic acid, and IL-3, IL-7, SCF, and FLT3. The results were
Fig. 2 Myeloid and NK-lymphoid potential assessment of CHIR99021-induced HE and OP9 coculture-derived progenitors. a Myeloid potential
assessment of CHIR99021 derived HE by quantitative colony forming unit (CFU) assay. Error bars are SEM. b Relative proportion of the different
types of colonies formed after CHIR99021 induction compared to OP9 coculture induction with and without VEGF. c Phase-contrast images of
colony morphology and corresponding cytospin images of E, M, GM, and GEMM colonies formed in semi-solid medium after CHIR99021 induction.
d Phase-contrast images of colony morphology and corresponding cytospin images of E, M, GM, and GEMM colonies formed in semi-solid medium
after OP9 co-culture induction. e Comparison of CHIR99021-induced and OP9 coculture-induced flow percentages of CD15–, CD56+, and CD56+CD16+
cells after 2 and 4 weeks of culture in lymphoid differentiation medium. The analyzed cells are gated on CD45+ fraction with side scatter characteristics
for lymphoid-like cells. Error bars are SEM. f Representative phase-contrast images of cells floating on OP9-DLL4 and representative flow analysis
showing CD45+ cells. R1, region of CD45+ cells with side scatter characteristics of lymphoid-like cells. g Representative flow cytometry analysis showing
the percentage of CD15– lymphoid fraction of differentiating cells and representative flow analysis showing the expression of CD56+ and CD16+ cells
gated on CD15– fraction. E erythroid, M macrophage, G granulocyte component of the GM colony, GM granulocyte/macrophage, GEMM granulocyte,
erythroid, monocyte and megakaryocyte colonies
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assessed by FACS analysis at approximately 2 weeks
(when the cells exhibited the most rapid proliferation ac-
tivity) and 4 weeks of OP9-DLL4 coculture. The results
of flow experiments are summarized in Fig. 2e. The scat-
ter of analyzed floating CD45+ cells showed two distinct
cell populations (R1 and R2), where R1 scatter was
characteristic for lymphoid cells. The gating strategy
(Additional file 1: Figure S1C) revealed that all lymphoid
cells were contained within the R1 population. Overall,
flow cytometric analysis demonstrated that, with little
variation, CHIR99021-induced HE generated a much
greater R1 CD45+ fraction (~80%) with side scatter char-
acteristic for lymphoid cells which contained an NK cell
population compared to that induced by OP9 coculture
(~14%) (Fig. 2f ).
In order to distinguish between lymphoid cells and
the cells of myeloid lineage we employed CD15, a
myeloid marker that is expressed by monocytes and
granulocytes but not lymphoid cells [39]. We have
found that about 60% of the cells within the CD45+
fraction with side scatter characteristic for lymphoid
cells were negative for CD15 at 2 weeks of differenti-
ation. After 4 weeks of OP-DL4 coculture, >97% of
all cells were negative for CD15.
The analysis of cells gated on the CD15– lymphoid
fraction showed that after 2 weeks of differentiation
CHIR990921-induced HE developed a much larger
population of CD56+ NK cells (~25%) compared to
OP9-induced cells (~15%), and the fraction of CD56+
CD16+ double-positive NK cells, the major population
subset of NK cells at this stage of development, was
small for both CHIR990921 and OP9-induced cells
(Fig. 2g). Notably, CHIR990921-induced progenitors
yielded a larger CD56+CD16– fraction, the minor
population of NK cells that is present in peripheral
blood. By 4 weeks of differentiation, NK cells derived
using the OP9 coculture method remained mostly
CD56+ single positive, while ~20% of lymphoid cells
derived from HE induced via CHIR99021 became
double positive for CD56+CD16+. This result suggests
that CHIR99021-induced progenitors may mature
more quickly in culture.
These findings demonstrate that the HE derived by the
method described here is capable of NK-lymphoid cell
differentiation in conditions that are suitable for various
types of immature NK cell derivation and potentially can
be manipulated for large-scale mature NK cell produc-
tion for clinical use as well as disease modeling and drug
screening.
CHIR99021-induced hemogenic endothelium is capable of
T-cell and B-cell differentiation
In order to assess the T-cell and B-cell potential of
CHIR99021-induced HE, we used flow cytometry to
analyze the CD45+ cells gated on the lymphoid fraction
for T-cell and B-cell markers. The analysis demonstrated
that after 3 weeks of differentiation on OP9-DLL4, up to
10% of these cells began to express CD3. This result was
comparable with the percentage of CD3+ cells we ob-
tained via the OP9 coculture induction method (data
not shown). Up to 3% of CD3+ cells were also double posi-
tive for markers CD4 and CD8 (Fig. 3a). Furthermore,
most lymphoid CD3+ T-cell progenitors underwent
some degree of T-cell receptor (TCR) rearrangement
generating predominantly αβ (61%) and some γδ
(29%) expression after 4 weeks of differentiation
(Fig. 3b), indicating that our OP9-DLL4 coculture sys-
tem produces T cells that undergo initial stages of
maturation. In order for T-cell progenitors to pro-
gress to mature phenotypes, a specific antigen stimu-
lation system should be implemented [40].
Notably, CHIR99021 induction promotes differenti-
ation of B cells (Fig. 3c). Currently, there are very few
studies, conducted using MS-5 stroma, that demonstrate
a limited lymphoid B-cell potential of pluripotent cells
in their differentiation systems [18].
Overall, using our CHIR99021 induction method we
were able to obtain ~2.5 × 105 CD56+ NK-lymphoid cells, ~
3.5 × 104 CD3+ T-lymphoid cells, and ~1.0 × 104 B-
lymphoid cells per 105 cells plated, as compared to the OP9
coculture induction method, which generated only ~6.7 ×
104 CD56+ NK-lymphoid cells, ~3.0 × 103 of CD3+ T-
lymphoid cells, and no B-lymphoid cells (Fig. 3d).
Myeloid population produced by CHIR990921-induced
hemogenic endothelium is different from myeloid
population produced with OP9 coculture
To identify the myeloid cells remaining in CD15+ mye-
loid populations, we analyzed hematopoietic cultures
growing in suspension by flow cytometry and morpho-
logical analysis of Wright-stained cytospins. We found
that these cells did not express CD56 or CD94 (data not
shown), but had variable expression of CD16, indicating
that the population comprised a variety of monocytes
and granulocytes. Interestingly, at 2 weeks the OP9 co-
culture induction protocol yielded a population of cells
that was predominantly CD15+CD16+ (Fig. 3e), while
the population of CHIR99021-induced cells was much
less homogeneous (Fig. 3f ), suggesting that CHIR99021
induction enhances the development of multipotential
progenitors resulting in a wider spectrum of myeloid
cells.
Discussion
Our study offers an important insight into the early
stages of hematopoietic specification of pluripotent stem
cells. The data show that multipotential hematopoietic
progenitors can be established in a relatively simple
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adherent system by promoting the stages of primitive
mesendoderm precursors, angiohematopoietic progeni-
tors, and HE with a GSK3 inhibitor, which points to the
key role of Wnt–b-catenin signaling in definitive
hematopoietic development. This finding provides an
efficient method of hPSC differentiation to HE that is
capable of definitive hematopoiesis, without the use of
cytokines in a defined serum-free system. Further studies
are needed to clarify whether GSK3 inhibitor reflects the
requirement of the hematopoietic niche in vivo or sim-
ply creates a benefit promoting hematopoiesis in tissue
culture.
There are several reports of hematopoietic differenti-
ation of hPSCs with the aid of the murine-derived OP9
stromal cell coculture, or feeder-free EB formation sys-
tems [20, 41–43]. The overall efficiency of hematopoietic
development using the stromal cells is relatively limited
[16], whereas the EB induction method requires the use
of expensive cytokines and complicates determination of
hematopoietic–stromal cell interactions. Furthermore,
both of these methods have undefined factors produced
either by the stromal cell or the 3D interaction. Using
the OP9 coculture protocol makes it impossible to con-
trol the cytokines secreted by the stromal cells, and the
Fig. 3 T-lymphoid, B-lymphoid, and myeloid potential assessment of CHIR99021-induced HE and OP9 coculture-derived progenitors. a Represen-
tative flow cytometry analysis showing the differentiating cells gated on the lymphoid fraction containing the CD3+ T-cell population and the per-
centage of CD4+CD8+ double-positive T cells after 3 weeks of differentiation. b Representative flow cytometry analysis showing TCRαβ and TCRγδ
rearrangements gated on CD3+ cells after 4 weeks of differentiation. c Representative flow cytometry analysis demonstrating the percentage of
cells expressing B-lymphoid potential (CD19). d Yield of CD56+, CD3+, and CD19+ cells per 1 × 105 cells plated. Error bars are SEM. e Representative
cytometric analysis of cells derived after OP9 coculture induction gated on CD15+ myeloid fraction, and cytospin images of floating cells showing
a variety of hematopoietic cell types. f Representative cytometric analysis of cells derived after CHIR99021 induction gated on CD15+ myeloid frac-
tion, and cytospin images of floating cells showing a variety of hematopoietic cell types. TCR T-cell receptor
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sphere-like structure of the embryoid bodies complicates
determination of hematopoietic niche components.
The monolayer CHIR99021 induction method de-
scribed here allows control of all of the variables
aside from the cell line response. Differentiation in
defined serum-free monolayer culture was reported
previously, but until now the “monolayer” system only
allowed hPSCs to differentiate into “primitive”
hematopoietic progenitor cells (HPCs) [44] and devel-
opment of T cells was not attained [43].
Monolayer induction based on GSK3 inhibition,
described here, yields a large number of HE cells
that can then differentiate further into various types
of myeloid and lymphoid lineages. Myeloid potential
was demonstrated by a range of myeloid CFUs,
consisting of CFU-E, CFU-GM, CFU-M, and CFU-
GEMM, as well as CD15+ cells produced after
2 weeks of OP9-DLL4 coculture. Substantial num-
bers of NK cells and some T cells and B-cell precur-
sors that developed after subsequent coculture of HE
with OP9-DLL4 demonstrated the strong lymphoid
potential of this differentiation system. Notably, this
system favors NK cells, which perhaps reflects a bias
of the formulation of the cytokine cocktail at the
OP9-DLL4 differentiation stage. A similar
observation that lymphoid development of hPSC-
derived cells strongly favors the NK-cell lineage was
reported previously by the Kaufman laboratory [45].
Although it is evident that the cytokines may be
omitted at the initial stages of progenitor develop-
ment, they may potentially change the lineage prefer-
ence or functionality of mature phenotypes. For
instance, Pearson et al. [46] demonstrated engraft-
ment of Flk1+ mesodermal cells generated from
mouse ESCs. The authors believe that the lack of SCF,
IL-3, and IL-6 hematopoietic cytokines in the culture pre-
vented differentiation and allowed for the accumulation of
engraftable cells.
Recently several promising applications have been
shown for hPSC-derived lymphocytes, such as adoptive
cell transfer immunotherapy (ACT) for treatment of
patients with cancer [12, 47], viral diseases [48], and
regaining self-tolerance by delivering regulatory T
cells [49]. In turn, hPSC-derived NK cells exhibit po-
tent antitumor activity without the need for human
leukocyte antigen matching and without prior antigen
exposure [16]. These cells were also recently
employed for treatment of ovarian cancer in a mouse
model [50]. Our study substantiates an efficient,
controllable, and less expensive approach to
hematopoietic cell derivation compared to existing
technologies, which may fulfill a growing need for
translational medicine for a scalable production of
lymphoid and myeloid cells.
Conclusion
This work demonstrates that specification of definitive
hematopoietic progenitors from hPSCs can proceed to
the HE stage in the presence of a small molecule GSK3
inhibitor without any additional cytokines. The defined
system presented here permits an investigation of the
influences of cytokines during the early stages of
hematopoietic cell fate commitment and development.
By combining an enhanced monolayer induction
method, which generates large quantities of HE, with a
mouse stromal coculture protocol, we have achieved an
efficient differentiation of hPSCs along various lympho-
myeloid lineages.
Additional file
Additional file 1: Figure S1. showing characterization of iPSC-SR2
and gating strategy for lymphoid cell analysis. (A) Normal karyotype of
iPSC-SR2. (B) Pluripotency assessment results of iPSC-SR2 by PluriTest.
(C) Gating strategy for identifying various lymphoid cells in differentiating
cultures after CHIR99021 induction and OP9 coculture induction. R1
representing CD45+ showing CD15, CD56, CD16, or CD94 expression,
while none of these markers are present on cells in R2. (TIF 10931 kb)
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